Clinical Study

Randomized Double Blind Placebo Controlled Study Of Erlotinib Or Placebo In Patients With Completely Resected Epidermal Growth Factor Receptor (Egfr) Mutant Non-Small Cell Lung Cancer (Nsclc)

Posted Date: Aug 17, 2017

  • Investigator: John Morris
  • Co-Investigator: Sarah Elizabeth Figueira
  • Specialties: Thoracic Surgery, Hematology/Oncology, Oncology, Cancer, Lung Cancer
  • Type of Study: Drug

The purpose of this study is to compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug). Researchers are trying to fi


To Be Eligible For This Study, Patients Must Have Early Stage Non-Small Cell Lung Cancer That Was Surgically Removed And May Have Been Treated With Chemotherapy And/Or Radiation.


A081105, Egfr, Non-Small Cell , Cancer, Lung

For More Information:

Uc Cancer Institute

  • Search Clinical Studies

  • Research in the News

    Ride Cincinnati Gives $200,000 in Grants for Breast Cancer Research

    Marlene Harris-Ride Cincinnati has continued its support of UC Cancer Institutescientists with the annual award of five grants to continue promising breastcancer research.